Innate Pharma (IPHA) Change in Cash (2019 - 2025)
Innate Pharma posted quarterly Change in Cash of -$44.6 million for Q4 2025, down 891.34% year-on-year from $5.6 million in Q4 2024, and down 891.34% on a QoQ basis from -$4.5 million in Q4 2024.
Innate Pharma (IPHA) has 7 years of Change in Cash data on file, last reported at -$44.6 million in Q4 2025.
- For the quarter ending Q4 2025, Change in Cash fell 891.34% year-over-year to -$44.6 million; the trailing twelve-month figure through Dec 2025 stood at -$63.7 million (down 92.55% YoY), and the FY2025 full-year result was -$44.6 million, down 891.34% from the prior year.
- Change in Cash for Q4 2025 stood at -$44.6 million, down from -$4.5 million in the prior quarter.
- Across five years, Change in Cash topped out at -$1076.9 in Q2 2024 and bottomed at -$44.6 million in Q4 2025.
- The 5-year median for Change in Cash is -$14.7 million (2023), against an average of -$19.5 million.
- The widest annual swing landed in 2023, when Change in Cash plunged 1520.02%; it then jumped 99.99% in 2024.
- A 5-year view of Change in Cash shows it stood at -$37.8 million in 2021, then soared by 47.27% to -$19.9 million in 2022, then grew by 26.47% to -$14.7 million in 2023, then jumped by 69.31% to -$4.5 million in 2024, then plunged by 891.34% to -$44.6 million in 2025.
- The last three Change in Cash figures came in at -$44.6 million (Q4 2025), -$4.5 million (Q4 2024), and -$1076.9 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 623.00 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 417.10 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | -153.10 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Innate Pharma | 199.64 Mn | 199.64 Mn | - | -44.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -44.59 Mn |
| Dec 31, 2024 | -4.50 Mn |
| Jun 30, 2024 | -1,076.89 |
| Dec 31, 2023 | -14.65 Mn |
| Jun 30, 2023 | -13.95 Mn |
| Dec 31, 2022 | -19.93 Mn |
| Jun 30, 2022 | -861,114.75 |
| Dec 31, 2021 | -37.79 Mn |
| Jun 30, 2021 | -39.51 Mn |
| Dec 31, 2020 | -78.81 Mn |
| Jun 30, 2020 | -78.58 Mn |
| Jun 30, 2019 | -3.30 Mn |